Zervimesine Advances to Phase 3 in DLB Psychosis on Undisclosed Data, Racing a Cash Runway into Q4 2027

Cognition Therapeutics Updates on Planned Phase 3 for DLB Psychosis

Cognition Therapeutics reported its second-quarter 2026 financial results and provided a business update, highlighting significant progress in its clinical and corporate priorities. The company held discussions with the FDA regarding the design of a planned Phase 3 trial for zervimesine in dementia with Lewy bodies (DLB) psychosis, aiming to initiate the study in mid-2027 with an improved tablet composition. Financially, Cognition reported approximately $34.8 million in cash and equivalents as of June 30, 2026, with an estimated cash runway into the fourth quarter of 2027. The net loss for the quarter was $3.9 million, an improvement from $6.7 million in the prior year.

• Cognition Therapeutics advanced its lead candidate, zervimesine, by conducting a planned meeting with the FDA to discuss the design of a registrational Phase 3 study for dementia with Lewy bodies (DLB) psychosis. The company plans to initiate this pivotal study in mid-2027, incorporating an improved tablet composition for the investigational once-daily oral therapy.
• The company received a Notice of Allowance for a new patent application covering the composition of matter, production process, and therapeutic method for zervimesine. Once issued, this patent is expected to extend intellectual property protection for zervimesine through 2045, significantly reinforcing the long-term value of its pipeline.
• Cognition Therapeutics reported a strong financial position with $34.8 million in cash, cash equivalents, and restricted cash equivalents as of June 30, 2026. Combined with $21.6 million in obligated grant funds, the company projects sufficient cash to fund its operations and capital expenditures into the fourth quarter of 2027, supporting ongoing and planned clinical activities.

FDA Alignment Paves Way for Zervimesine's Phase 3 in DLB Psychosis

Recent clinical investigations in Dementia with Lewy Bodies (DLB) psychosis have emphasized a range of endpoints centered on validated assessment scales and symptom characterization. Key instruments for measuring change include the Neuropsychiatric Inventory (NPI), the Scales for Outcomes in Parkinson's Disease-Psychiatric Complications (SCOPA-PC), and the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). A notable development is the validation of the Psychosis and Hallucinations Questionnaire (PsycH-Q), a patient-friendly, self-report tool that demonstrates significant correlation with established clinician-rated scales. These endpoints are critical, as psychosis is highly prevalent in DLB (up to 74%), with hallucinations and delusions being more common than in Alzheimer's disease. Furthermore, studies consistently link these psychotic symptoms to poorer functional and clinical outcomes, including impaired activities of daily living (ADLs) and co-morbid depression.

Alongside clinical scales, emerging endpoints are focusing on objective biomarkers to track disease progression and treatment response. Fluid biomarkers are of particular interest, with studies indicating that lower plasma concentrations of phosphorylated tau-181 (p-tau181) and p-tau231 are associated with persistent hallucinations and an increased risk of neuropsychiatric symptoms in early-stage DLB. Conversely, higher levels of these p-tau species are associated with a lower longitudinal risk. There is also evidence for a synergistic interaction between hallucinations and p-tau231, which may exacerbate cognitive decline when Alzheimer's disease co-pathology is present. These fluid biomarker findings are complemented by neuropathological data confirming a direct effect of Lewy body pathology on hallucinations and imaging biomarkers like DAT-SPECT and FDG-PET, which show promise for monitoring clinical progression.

Navigating the Challenges of Current DLB Psychosis Treatments

Managing psychosis in patients with Dementia with Lewy Bodies (DLB) presents significant clinical challenges, primarily stemming from the population's unique vulnerability to standard treatments. The use of antipsychotic medications is particularly perilous, as these agents can precipitate severe adverse reactions and paradoxically worsen the very symptoms they are intended to manage, leading to a complex risk-benefit calculation for clinicians.

• A primary challenge is the profound neuroleptic hypersensitivity characteristic of DLB, which leads to excessive morbidity and mortality. The use of traditional antipsychotics can double or triple the mortality rate and precipitate severe adverse events, including somnolence, sedation, delirium, cerebrovascular events, and severe extrapyramidal symptoms.

• Antidopaminergic medications, including antipsychotics, frequently worsen the core clinical features of the disease. Instead of providing relief, these drugs can exacerbate motor parkinsonism, accelerate cognitive decline, and intensify the underlying neuropsychiatric disturbances they are meant to treat.

• The efficacy of available pharmacological options is limited across the board. Antipsychotics have demonstrated only modest efficacy for treating psychosis and agitation in dementia populations. Furthermore, studies on other agents, such as the cholinesterase inhibitor donepezil, have failed to show a statistically significant superiority over placebo for behavioral symptoms in a key Phase III trial.

• Clinicians face a difficult therapeutic dilemma, as antipsychotics should be reserved for severe symptoms that have failed nonpharmacological management and first-line agents like trazodone or cholinesterase inhibitors. Despite this, a lack of physician awareness of treatment needs and systemic care gaps can lead to unfavorable treatment patterns, including high rates of antipsychotic use in some care settings despite the well-documented risks.

Shifting Paradigms in DLB Psychosis Treatment Landscape

Over the past five years, the treatment landscape for psychosis in Dementia with Lewy Bodies (DLB) has evolved from a reliance on cholinesterase inhibitors and cautious use of traditional antipsychotics to the investigation of novel agents with more targeted mechanisms. Acetylcholinesterase inhibitors remain a cornerstone, with donepezil holding level-1 evidence for managing hallucinations (SMD=-0.52; p=0.02) and rivastigmine having level-2 evidence for neuropsychiatric symptoms. However, the primary shift has been toward agents with better safety profiles, driven by the well-documented risk of antidopaminergic medications worsening motor and cognitive function. Pimavanserin, a serotonin 5-HT2A receptor inverse agonist FDA-approved for Parkinson's disease psychosis, has emerged as a promising option. Case series and studies have shown it is well-tolerated and can significantly improve psychosis in DLB patients, sometimes in combination with trazodone, even in those who have failed traditional antipsychotics or clozapine.

Alongside pimavanserin, several other atypical antipsychotics are being explored, reflecting a search for effective treatments that avoid the severe neuroleptic sensitivity common in DLB. A case report on lumateperone demonstrated a favorable response in psychotic symptoms, cognition, and sleep without inducing extrapyramidal side effects. Similarly, brexpiprazole has shown potential, with one report noting efficacy at a high dose (4 mg/day) without adverse effects. An open-label study of aripiprazole also showed it may be effective and well-tolerated for psychotic symptoms in DLB. Low-dose loxapine has also been used effectively in patients unable to tolerate other antipsychotics. This exploration of repurposed and novel agents highlights a trend toward individualized therapy, aiming to find a tolerable option for a patient population where agents like olanzapine have been shown to precipitate significant clinical worsening.

This evolving pharmacopeia is complemented by a greater emphasis on risk mitigation and non-pharmacological approaches. The pronounced sensitivity of DLB patients to antipsychotic side effects has reinforced clinical practice guidelines conditionally recommending agents like risperidone while underscoring that acetylcholinesterase inhibitors should be the first-line treatment. To support clinical decision-making, tools such as electronic health record (EHR) Best Practice Alerts are being implemented to help providers identify patients prone to neuroleptic sensitivity. For severe, treatment-refractory cases of psychosis or catatonia, evidence now supports the use of electroconvulsive therapy (ECT) as a valuable and well-tolerated alternative when pharmacotherapy is too challenging, demonstrating short-term efficacy in LBD comparable to that seen in schizophrenia.